List of Contents

Mouth Ulcer Treatment Market Size, Share, and Trends 2024 to 2034

The global mouth ulcer treatment market size is calculated at USD 1.62 billion in 2024, grew to USD 1.68 billion in 2025, and is predicted to hit around USD 2.37 billion by 2034, poised to grow at a CAGR of 3.9% between 2024 and 2034. The North America mouth ulcer treatment market size accounted for USD 710 million in 2024 and is anticipated to grow at the fastest CAGR of 3.99% during the forecast year.

  • Last Updated : October 2024
  • Report Code : 3409
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Mouth Ulcer Treatment Market 

5.1. COVID-19 Landscape: Mouth Ulcer Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Mouth Ulcer Treatment Market, By Drug Class

8.1. Mouth Ulcer Treatment Market, by Drug Class, 2024-2034

8.1.1. Antimicrobial

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Antihistamine

8.1.2.1. Market Revenue and Forecast (2021-2034)

8.1.3. Antihistamine

8.1.3.1. Market Revenue and Forecast (2021-2034)

8.1.4. Others

8.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Mouth Ulcer Treatment Market, By Formulation

9.1. Mouth Ulcer Treatment Market, by Formulation, 2024-2034

9.1.1. Sprays

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Mouthwash

9.1.2.1. Market Revenue and Forecast (2021-2034)

9.1.3. Gels

9.1.3.1. Market Revenue and Forecast (2021-2034)

9.1.4. Lozenges

9.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Mouth Ulcer Treatment Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.1.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.1.3.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.1.4.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.2.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.2.3.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.2.4.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.2.5.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.2.6.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.3.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.3.3.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.3.4.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.3.5.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.3.6.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.4.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.4.3.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.4.4.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.4.5.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.4.6.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.5.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.5.3.2. Market Revenue and Forecast, by Formulation (2021-2034)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)

10.5.4.2. Market Revenue and Forecast, by Formulation (2021-2034)

Chapter 11. Company Profiles

11.1. 3M Company

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Blistex Inc.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. GSK plc

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Church & Dwight Co. Inc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Colgate-Palmolive Company

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Patterson Dental Supply Inc.

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Pfizer Inc.

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Dr. Reddy's Laboratories Ltd

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Prince Care Pharma Private Limited

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Bristol Myers Squibb Company

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client